Biotech Startups: Nothing Ventured, Nothing Gained
It’s a rotten time to be raising money. And for small biotechnology companies most of which have little or no revenue and are dependent on investor capital to stay afloat times are tough indeed. According to the Wall Street Journal 120 of the 360 publicly traded biotech firms have less than 6 months of cash on hand. And while this isn’t an entirely foreign position for industry upstarts to be in the challenging fundraising environment means many of these companies could go under. The business of developing experimental drugs procedures and devices has always been one of high risk and ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here